Atea Pharmaceuticals Inc (AVIR)

$3.37 +0.04 (1.20%)
Market Cap 281.26M
Revenue (ttm) 0.00
Net Income (ttm) -135.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 337,600
Avg Vol 400,164
Day's Range N/A - N/A
Shares Out 84.46M
Stochastic %K 63%
Beta 0.20
Analysts Hold
Price Target $6.20

Latest News on AVIR

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 7:00 AM EST - 9 days ago

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process

Dec 18, 2024, 5:05 PM EST - 4 weeks ago

Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

Dec 16, 2024, 5:00 AM EST - 4 weeks ago

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

Dec 4, 2024, 3:14 PM EST - 6 weeks ago

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

Dec 4, 2024, 7:00 AM EST - 6 weeks ago

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

Nov 26, 2024, 7:00 AM EST - 7 weeks ago

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Nov 15, 2024, 11:00 AM EST - 2 months ago

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 1:14 PM EST - 2 months ago

Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:05 PM EST - 2 months ago

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Oct 30, 2024, 7:00 AM EDT - 2 months ago

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

Sep 13, 2024, 7:00 AM EDT - 4 months ago

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway

Aug 28, 2024, 7:00 AM EDT - 5 months ago

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway

Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript

Aug 11, 2024, 12:13 PM EDT - 5 months ago

Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript

Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024

Jul 31, 2024, 7:00 AM EDT - 6 months ago

Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 29, 2024, 7:00 AM EDT - 8 months ago

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

May 22, 2024, 7:00 AM EDT - 8 months ago

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Atea Pharmaceuticals, Inc. (AVIR) Q1 2024 Earnings Call Transcript

May 14, 2024, 10:00 PM EDT - 8 months ago

Atea Pharmaceuticals, Inc. (AVIR) Q1 2024 Earnings Call Transcript

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024

Apr 29, 2024, 7:00 AM EDT - 9 months ago

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Mar 27, 2024, 7:00 AM EDT - 10 months ago

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 11:24 PM EST - 11 months ago

Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 4:05 PM EST - 11 months ago

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

Feb 21, 2024, 7:00 AM EST - 11 months ago

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

Jan 8, 2024, 4:05 PM EST - 1 year ago

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

Nov 13, 2023, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

Atea Pharmaceuticals, Inc. (AVIR) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 6:51 PM EST - 1 year ago

Atea Pharmaceuticals, Inc. (AVIR) Q3 2023 Earnings Call Transcript

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 4:05 PM EST - 1 year ago

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Nov 8, 2023, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023

Nov 1, 2023, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023

Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 6, 2023, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 8, 2023, 4:05 PM EDT - 1 year ago

Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

Aug 1, 2023, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

Atea Pharmaceuticals' Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra Biosciences

May 30, 2023, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals' Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra Biosciences

Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra Biosciences

May 23, 2023, 4:05 PM EDT - 1 year ago

Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra Biosciences

Atea Pharmaceuticals, Inc. (AVIR) Q1 2023 Earnings Call Transcript

May 8, 2023, 8:51 PM EDT - 1 year ago

Atea Pharmaceuticals, Inc. (AVIR) Q1 2023 Earnings Call Transcript

Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

May 8, 2023, 4:05 PM EDT - 1 year ago

Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023

May 1, 2023, 4:05 PM EDT - 1 year ago

Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19

Apr 25, 2023, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19

Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases

Apr 12, 2023, 7:00 AM EDT - 1 year ago

Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research

Mar 14, 2023, 7:00 AM EDT - 2 years ago

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research

Mar 8, 2023, 7:00 AM EST - 2 years ago

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research

Atea Pharmaceuticals, Inc. (AVIR) Q4 2022 Earnings Call Transcript

Feb 28, 2023, 10:14 PM EST - 2 years ago

Atea Pharmaceuticals, Inc. (AVIR) Q4 2022 Earnings Call Transcript

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Feb 28, 2023, 4:05 PM EST - 2 years ago

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023

Feb 23, 2023, 7:00 AM EST - 2 years ago

Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023

Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023

Feb 21, 2023, 7:00 AM EST - 2 years ago

Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023

Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections

Feb 15, 2023, 4:05 PM EST - 2 years ago

Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections

Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

Feb 7, 2023, 7:00 AM EST - 2 years ago

Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

Atea Pharmaceuticals Highlights Strategic Priorities for 2023

Jan 9, 2023, 7:00 AM EST - 2 years ago

Atea Pharmaceuticals Highlights Strategic Priorities for 2023

Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 4, 2023, 7:00 AM EST - 2 years ago

Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19

Nov 29, 2022, 7:00 AM EST - 2 years ago

Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19